Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432626 · ClinicalTrials.gov registry record · NA
Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG
A NA study of Stress Induced Cardiomyopathy, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01432626: Completed NA study of Stress Induced Cardiomyopathy, sponsored by University of Pittsburgh.
NCT01432626 is a NA study of Stress Induced Cardiomyopathy that has completed, run by University of Pittsburgh. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01432626, a NA study of Stress Induced Cardiomyopathy, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective: The objective of this pilot study is to characterize the cardiac uptake patterns of I-123 mIBG in stress-induced (Takotsubo's) cardiomyopathy. Hypothesis: Perturbations in sympathetic innervation are the underlying pathogenesis of stress induced cardiomyopathy and will result in abnormalities in I-123 mIBG cardiac imaging. Thus, planar and SPECT I-123 MIBG imaging will provide insight into the pathogenesis of stress-induced cardiomyopathy, and may lead to the development of more specific diagnostic criteria. Study design: This proposal is for a prospective pilot study to characterize perturbations in cardiac sympathetic innervation in patients with stress induced cardiomyopathy by performing planar and SPECT I-123 MIBG imaging during the acute presentation and after recovery of LV function.
Primary Outcome
Number of participants who had an abnormal regional uptake of I-123 mIBG at baseline (acute phase) and the number of participants who had an abnormal I-123 mIBG uptake on follow up (recovery phase)
Conditions Studied
Interventions
- DRUG I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-06 |
| Phase | NA |
What the finished NCT01432626 record still lists
NCT01432626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Stress Induced Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which I-123 radiolabeled metaiodobenzylguanidine cardiac imaging is the first listed.
NCT01432626 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01432626 about?
NCT01432626 is a clinical study titled "Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG". Objective: The objective of this pilot study is to characterize the cardiac uptake patterns of I-123 mIBG in stress-induced (Takotsubo's) cardiomyopathy. Hypothesis: Perturbations in sympathetic innervation are the underlying pathogenesis of stress induced cardiomyopathy and will result in abnormal...
What is the current status of trial NCT01432626?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2011-09. Estimated completion is 2015-06.
What conditions does trial NCT01432626 study?
This clinical trial studies the following conditions: Stress Induced Cardiomyopathy.
What interventions are being tested in trial NCT01432626?
The interventions under investigation include: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging (DRUG).
Who is sponsoring clinical trial NCT01432626?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01432626 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01432626's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia